Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Berubicin hydrochloride by CNS Pharmaceuticals for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Berubicin hydrochloride is under clinical development by CNS Pharmaceuticals and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...
Data Insights
Berubicin hydrochloride by CNS Pharmaceuticals for Glioblastoma Multiforme (GBM): Likelihood of Approval
Berubicin hydrochloride is under clinical development by CNS Pharmaceuticals and currently in Phase II for Glioblastoma Multiforme (GBM). According to...